Linagliptin
Active ingredient: Linagliptin
In short: Linagliptin tablet is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Limitations of Use Linagliptin should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in t
What is Linagliptin used for?
Linagliptin
tablet is indicated as an adjunct to diet and exercise to improve
glycemic control in adults with type 2 diabetes mellitus
.
Limitations of Use
Linagliptin should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.
Linagliptin has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using linagliptin
.
Linagliptin dosage
The recommended dose of linagliptin is 5 mg
once daily.
Linagliptin tablets can
be taken with or without food.
How to take Linagliptin — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Pancreatitis
Inform patients that acute pancreatitis
has been reported during use of linagliptin. Inform patients
that persistent severe abdominal pain, sometimes radiating to the
back, which may or may not be accompanied by vomiting, is the hallmark
symptom of acute pancreatitis. Instruct patients to discontinue linagliptin
promptly and contact their physician if persistent severe abdominal
pain occurs .
Heart Failure
Inform patients of the signs and symptoms of heart failure. Before initiating linagliptin, patients should be asked about a history of heart failure or other risk factors for heart failure including moderate to severe renal impairment. Instruct patients to contact their healthcare provider as soon as possible if they experience symptoms of heart failure, including increasing shortness of breath, rapid increase in weight or swelling of the feet .
Hypoglycemia
Inform patients that the incidence of hypoglycemia
is increased when linagliptin is added to a sulfonylurea or insulin
and that a lower dose of the sulfonylurea or insulin may be required
to reduce the risk of hypoglycemia
. …
Warnings & precautions
Do not take this medicine if: Linagliptin is contraindicated in patients with
a history of a hypersensitivity reaction to linagliptin, such as anaphylaxis,
angioedema, exfoliative skin conditions, urticaria, or bronchial Linagliptin is contraindicated in patients with hypersensitivity to linagliptin or any of the excipients in linagliptin tablets, reactions such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity have occurred
.
Acute pancreatitis, including fatal pancreatitis, has been reported in patients treated with linagliptin.
Take careful notice of potential signs and symptoms
of pancreatitis. If pancreatitis is suspected, promptly discontinue
linagliptin and initiate appropriate management. It is unknown whether
patients with a history of pancreatitis are at increased risk for
the development of pancreatitis while using linagliptin.
An association between DPP-4 inhibitor treatment and heart failure has been observed in cardiovascular outcomes trials for two other members of the DPP-4 inhibitor class. These trials evaluated patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease.
Consider the risks and benefits of linagliptin prior to initiating treatment in patients at risk for heart failure, such as those with a prior history of heart failure and a history of renal impairment, and observe these patients for signs and symptoms of heart failure during therapy. Advise patients of the characteristic symptoms of heart failure and to immediately report such symptoms. If heart failure develops, evaluate and manage according to current standards of care and consider discontinuation of linagliptin.
Insulin secretagogues and insulin are known to cause hypoglycemia. …
Linagliptin side effects
The following serious adverse reactions are described below or elsewhere in the prescribing information:
Pancreatitis
Heart Failure
Use with Medications Known to Cause Hypoglycemia
Hypersensitivity Reactions
Severe and Disabling Arthralgia
Bullous Pemphigoid
Because clinical
trials are conducted under widely varying conditions, adverse reaction
rates observed in the clinical trials of a drug cannot be directly
compared to rates in the clinical trials of another drug and may not
reflect the rates observed in practice.
The safety evaluation of linagliptin 5 mg once daily in
patients with type 2 diabetes is based on 14 placebo-controlled trials, 1 active-controlled study, and one study in patients with severe renal impairment. In the 14 placebo-controlled studies, a total of 3625
patients were randomized and treated with linagliptin 5 mg daily and
2176 with placebo. The mean exposure in patients treated with linagliptin
across studies was 29.6 weeks. The maximum follow-up was 78 weeks.
Linagliptin 5 mg once daily was studied as
monotherapy in three placebo-controlled trials of 18 and 24 weeks’
duration and in five additional placebo-controlled studies lasting
≤18 weeks. …
Drug interactions
Rifampin
decreased linagliptin exposure, suggesting that the efficacy of linagliptin
may be reduced when administered in combination with a strong P-gp
or CYP3A4 inducer. Therefore, use of alternative treatments is strongly
recommended when linagliptin is to be administered with a strong P-gp
or CYP3A4 inducer
.
Coadministration of linagliptin with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia
.
About this medicine
Linagliptin tablets contain,
as the active ingredient, an orally-active inhibitor of the dipeptidyl
peptidase-4 (DPP-4) enzyme.
Linagliptin
is described chemically as 1H-Purine-2,6-dione, 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-
The empirical formula is C
25H
28N
8O
2 and the molecular weight is 472.54 g/mol. The structural formula
is:
Linagliptin is a white to yellowish, not or only slightly hygroscopic
solid substance. It is very slightly soluble in water (0.9 mg/mL).
Linagliptin is soluble in methanol (ca. 60 mg/mL), sparingly soluble
in ethanol (ca. 10 mg/mL), very slightly soluble in isopropanol (<1
mg/mL), and very slightly soluble in acetone (ca. 1 mg/mL).
Each film-coated tablet of linagliptin contains
5 mg of linagliptin free base and the following inactive ingredients:
mannitol, pregelatinized starch, copovidone, and magnesium
stearate. In addition, the film coating contains the following inactive
ingredients: hypromellose, titanium dioxide and polyethylene glycol. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID cbdbd4b2-c07b-00e1-e053-2995a90a5fc9. Read the full official label on DailyMed.
Related medicines
Atorvastatin Metformin Losartan Semaglutide Insulin Glargine Empagliflozin Glipizide Insulin Lispro